The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
What unusual toxicities are seen in patients with ALL and what are the best strategies to manage them?
Featured:
Charles Mullighan
José María Ribera
Helene Hallböök
Kjeld Schmiegelow
Anita Rijneveld
Oliver Ottmann
André BaruchelDuring the ALL Hub Steering Committee meeting, members discussed ongoing research to address unmet needs in the assessment and management of unusual and severe toxicities, in in both pediatric and adult acute lymphoblastic leukemia. This discussion was chaired by Kjeld Schmiegelow and featured Helene Hallböök, José María Ribera, Anita Rijneveld, André Baruchel, Oliver Ottmann, and Charles Mullighan.
What unusual toxicities are seen in patients with ALL and what are the best strategies to manage them?
The key unmet needs identified include global uniformity in the definition and management of unusual toxicities, evaluation of the long-term effects in patients experiencing toxicities, and re-exposure to novel therapies following toxicities.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content